7. Systemisk behandling

Abou-Alfa, G. K. L. G. M. K. e. a. (2022). Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evidence, 1(8)

Bruix, J., Takayama, T., Mazzaferro, V., Chau, G. Y., Yang, J., Kudo, M., Cai, J., Poon, R. T., ... investigators, S. (2015). Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncology, 16(13), 1344-54.

Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y. H., Bodoky, G., Pracht, M., Yokosuka, O., ... Investigators, R. (2017). Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 389(10064), 56-66.

Costa, L. B., Queiroz, M. A., Barbosa, F. G., Nunes, R. F., Zaniboni, E. C., Ruiz, M. M., Jardim, D., Gomes Marin, J. F., ... Buchpiguel, C. A. (2021). Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism. Radiographics, 41(1), 120-143.

Kelley, R. K., Meyer, T., Rimassa, L., Merle, P., Park, J. W., Yau, T., Chan, S. L., Blanc, J. F., ... Abou-Alfa, G. K. (2020). Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 26(18), 4795-4804.

Kudo, M., Finn, R. S., Qin, S., Han, K. H., Ikeda, K., Piscaglia, F., Baron, A., Park, J. W., ... Cheng, A. L. (2018). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, 391(10126), 1163-1173.

Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., ... Finn, R. S. (2021). Hepatocellular carcinoma. Nature reviews. Disease primers, 7(1), 6.

Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., de Oliveira, A. C., Santoro, A., ... Group, S. I. S. (2008). Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine, 359(4), 378-90.

Peng, Z., Fan, W., Zhu, B., Wang, G., Sun, J., Xiao, C., Huang, F., Tang, R., ... Kuang, M. (2022). Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH). Journal of Clinical Oncology, , JCO2200392.

Qin, S., Bai, Y., Lim, H. Y., Thongprasert, S., Chao, Y., Fan, J., Yang, T. S., Bhudhisawasdi, V., ... Sun, Y. (2013). Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. Journal of Clinical Oncology, 31(28), 3501-8.

Zhu, A. X., Kang, Y. K., Yen, C. J., Finn, R. S., Galle, P. R., Llovet, J. M., Assenat, E., Brandi, G., ... investigators, R. s. (2019). Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, 20(2), 282-296.